Business Context and Reporting Period
This Form 8-K filing by Lyell Immunopharma, Inc. (LYEL) reports on corporate governance and compensation matters approved by the Compensation Committee on February 11, 2022. The filing details amendments to the Officer Severance Plan, the establishment of 2022 base salaries for named executive officers, and the approval of 2021 annual bonus payments.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- 2022 Base Salaries (Effective March 1, 2022):
- Elizabeth Homans: $600,000
- Stephen Hill: $504,400
- Heather Turner: $473,481
- 2021 Annual Bonus Payments:
- Elizabeth Homans: $433,836
- Stephen Hill: $346,775
- Heather Turner: $295,925
- Rick Klausner: $222,007
Material Changes
The primary material change is the amendment and restatement of the Officer Severance Plan, effective February 11, 2022. Key enhancements to the previous plan include:
- Expanded Severance for Non-Change in Control Terminations: Addition of pro-rated bonus severance for Tier I employees and increased base salary/COBRA coverage for Tier II (9 months) and Tier III (6 months) employees.
- Enhanced Change in Control Protections: Addition of target annual bonus severance for Tier I employees and vesting acceleration benefits for Tier III employees during the Change in Control Protection Period.
- Vesting Acceleration Increase: The vesting acceleration percentage for Tier III employees was increased from 75% to 100%.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of operational risks. The document notes that the summary of the Amended Plan is not complete and refers investors to the full text of the plan, which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2021.
Investor Verification Checklist
- Verify the full text of the Amended Officer Severance Plan in the upcoming Form 10-K to understand specific definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the total number of employees eligible under the new Tier I, II, and III classifications to assess potential future liability.
- Review the 2021 Form 10-K to compare the new 2022 base salaries against prior year compensation trends.
- Monitor future filings for any actual severance payments triggered by the new plan terms.